Published 7 hours ago • loading... • Updated 7 hours ago
TALZENNA Plus XTANDI Improves Radiographic Progression-Free Survival by More Than 50% in Metastatic Prostate Cancer
Summary by Hastings Tribune
4 Articles
4 Articles
+3 Reposted by 3 other sources
TALZENNA Plus XTANDI Improves Radiographic Progression-Free Survival by More Than 50% in Metastatic Prostate Cancer
First PARP inhibitor + ARPI combination to show consistent rPFS improvement in HRR gene‑altered metastatic
Coverage Details
Total News Sources4
Leaning Left0Leaning Right0Center3Last Updated100% Center
Bias Distribution
- 100% of the sources are Center
100% Center
C 100%
Factuality
To view factuality data please Upgrade to Premium



